Compass Pathways (CMPS) Competitors

$10.87 +0.80 (+7.94%)

Closing price 04:00 PM Eastern

Extended Trading

$10.86 0.00 (-0.05%)

As of 07:58 PM Eastern

CMPS vs. IMVT, COGT, XENE, APLS, and GRFS

Should you buy Compass Pathways stock or one of its competitors? MarketBeat compares Compass Pathways with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Compass Pathways include Immunovant (IMVT), Cogent Biosciences (COGT), Xenon Pharmaceuticals (XENE), Apellis Pharmaceuticals (APLS), and Grifols (GRFS). These companies are all part of the "pharmaceutical products" industry.

How does Compass Pathways compare to Immunovant?

Compass Pathways (NASDAQ:CMPS) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, media sentiment, earnings, risk, analyst recommendations, dividends and valuation.

Compass Pathways has a beta of 2.39, suggesting that its stock price is 139% more volatile than the broader market. Comparatively, Immunovant has a beta of 0.7, suggesting that its stock price is 30% less volatile than the broader market.

Compass Pathways currently has a consensus target price of $20.58, indicating a potential upside of 89.36%. Immunovant has a consensus target price of $32.44, indicating a potential downside of 8.76%. Given Compass Pathways' stronger consensus rating and higher possible upside, analysts plainly believe Compass Pathways is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Pathways	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.92
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

Immunovant is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Pathways	N/A	N/A	-$287.86M	-$3.15	N/A
Immunovant	N/A	N/A	-$413.84M	-$2.69	N/A

In the previous week, Compass Pathways had 19 more articles in the media than Immunovant. MarketBeat recorded 32 mentions for Compass Pathways and 13 mentions for Immunovant. Compass Pathways' average media sentiment score of 0.73 beat Immunovant's score of -1.00 indicating that Compass Pathways is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compass Pathways	5 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunovant	6 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

46.2% of Compass Pathways shares are held by institutional investors. Comparatively, 47.1% of Immunovant shares are held by institutional investors. 2.8% of Compass Pathways shares are held by company insiders. Comparatively, 1.8% of Immunovant shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Compass Pathways' return on equity of -31.07% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Pathways	N/A	-31.07%	-11.40%
Immunovant	N/A	-63.17%	-58.01%

Summary

Compass Pathways beats Immunovant on 12 of the 14 factors compared between the two stocks.

How does Compass Pathways compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and Compass Pathways (NASDAQ:CMPS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership.

Cogent Biosciences has a beta of 0.37, suggesting that its stock price is 63% less volatile than the broader market. Comparatively, Compass Pathways has a beta of 2.39, suggesting that its stock price is 139% more volatile than the broader market.

46.2% of Compass Pathways shares are held by institutional investors. 7.3% of Cogent Biosciences shares are held by company insiders. Comparatively, 2.8% of Compass Pathways shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Compass Pathways' return on equity of -31.07% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-104.27%	-54.64%
Compass Pathways	N/A	-31.07%	-11.40%

Cogent Biosciences is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
Compass Pathways	N/A	N/A	-$287.86M	-$3.15	N/A

Cogent Biosciences presently has a consensus price target of $43.73, suggesting a potential upside of 32.83%. Compass Pathways has a consensus price target of $20.58, suggesting a potential upside of 89.36%. Given Compass Pathways' stronger consensus rating and higher possible upside, analysts plainly believe Compass Pathways is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
Compass Pathways	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.92

In the previous week, Compass Pathways had 32 more articles in the media than Cogent Biosciences. MarketBeat recorded 32 mentions for Compass Pathways and 0 mentions for Cogent Biosciences. Compass Pathways' average media sentiment score of 0.73 beat Cogent Biosciences' score of 0.00 indicating that Compass Pathways is being referred to more favorably in the news media.

Company	Overall Sentiment
Cogent Biosciences	Neutral
Compass Pathways	Positive

Summary

Compass Pathways beats Cogent Biosciences on 10 of the 13 factors compared between the two stocks.

How does Compass Pathways compare to Xenon Pharmaceuticals?

Compass Pathways (NASDAQ:CMPS) and Xenon Pharmaceuticals (NASDAQ:XENE) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation and institutional ownership.

Compass Pathways' return on equity of -31.07% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Pathways	N/A	-31.07%	-11.40%
Xenon Pharmaceuticals	N/A	-49.23%	-46.42%

46.2% of Compass Pathways shares are held by institutional investors. Comparatively, 95.5% of Xenon Pharmaceuticals shares are held by institutional investors. 2.8% of Compass Pathways shares are held by company insiders. Comparatively, 4.1% of Xenon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Compass Pathways currently has a consensus price target of $20.58, suggesting a potential upside of 89.36%. Xenon Pharmaceuticals has a consensus price target of $77.07, suggesting a potential upside of 40.94%. Given Compass Pathways' higher probable upside, equities analysts clearly believe Compass Pathways is more favorable than Xenon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Pathways	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.92
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Compass Pathways had 27 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 32 mentions for Compass Pathways and 5 mentions for Xenon Pharmaceuticals. Xenon Pharmaceuticals' average media sentiment score of 0.77 beat Compass Pathways' score of 0.73 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compass Pathways	5 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Xenon Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Compass Pathways has a beta of 2.39, indicating that its share price is 139% more volatile than the broader market. Comparatively, Xenon Pharmaceuticals has a beta of 0.65, indicating that its share price is 35% less volatile than the broader market.

Compass Pathways has higher earnings, but lower revenue than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Pathways	N/A	N/A	-$287.86M	-$3.15	N/A
Xenon Pharmaceuticals	$7.50M	704.79	-$345.91M	-$4.70	N/A

Summary

Compass Pathways beats Xenon Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Compass Pathways compare to Apellis Pharmaceuticals?

Apellis Pharmaceuticals (NASDAQ:APLS) and Compass Pathways (NASDAQ:CMPS) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, risk and valuation.

Apellis Pharmaceuticals has a net margin of 12.06% compared to Compass Pathways' net margin of 0.00%. Apellis Pharmaceuticals' return on equity of 39.71% beat Compass Pathways' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apellis Pharmaceuticals	12.06%	39.71%	13.20%
Compass Pathways	N/A	-31.07%	-11.40%

In the previous week, Compass Pathways had 26 more articles in the media than Apellis Pharmaceuticals. MarketBeat recorded 32 mentions for Compass Pathways and 6 mentions for Apellis Pharmaceuticals. Compass Pathways' average media sentiment score of 0.73 beat Apellis Pharmaceuticals' score of 0.00 indicating that Compass Pathways is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apellis Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Compass Pathways	5 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Apellis Pharmaceuticals has higher revenue and earnings than Compass Pathways. Compass Pathways is trading at a lower price-to-earnings ratio than Apellis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apellis Pharmaceuticals	$1.11B	4.75	$22.39M	$1.02	40.23
Compass Pathways	N/A	N/A	-$287.86M	-$3.15	N/A

Apellis Pharmaceuticals presently has a consensus price target of $35.72, indicating a potential downside of 12.94%. Compass Pathways has a consensus price target of $20.58, indicating a potential upside of 89.36%. Given Compass Pathways' stronger consensus rating and higher possible upside, analysts clearly believe Compass Pathways is more favorable than Apellis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apellis Pharmaceuticals	1 Sell rating(s)	18 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.09
Compass Pathways	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.92

Apellis Pharmaceuticals has a beta of -0.24, meaning that its share price is 124% less volatile than the broader market. Comparatively, Compass Pathways has a beta of 2.39, meaning that its share price is 139% more volatile than the broader market.

96.3% of Apellis Pharmaceuticals shares are held by institutional investors. Comparatively, 46.2% of Compass Pathways shares are held by institutional investors. 6.5% of Apellis Pharmaceuticals shares are held by insiders. Comparatively, 2.8% of Compass Pathways shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Apellis Pharmaceuticals beats Compass Pathways on 9 of the 16 factors compared between the two stocks.

How does Compass Pathways compare to Grifols?

Compass Pathways (NASDAQ:CMPS) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.

46.2% of Compass Pathways shares are owned by institutional investors. 2.8% of Compass Pathways shares are owned by company insiders. Comparatively, 0.2% of Grifols shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Grifols has a net margin of 5.54% compared to Compass Pathways' net margin of 0.00%. Grifols' return on equity of 6.21% beat Compass Pathways' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Pathways	N/A	-31.07%	-11.40%
Grifols	5.54%	6.21%	2.39%

In the previous week, Compass Pathways had 30 more articles in the media than Grifols. MarketBeat recorded 32 mentions for Compass Pathways and 2 mentions for Grifols. Compass Pathways' average media sentiment score of 0.73 beat Grifols' score of -0.17 indicating that Compass Pathways is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compass Pathways	5 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Grifols	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Grifols has higher revenue and earnings than Compass Pathways. Compass Pathways is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Pathways	N/A	N/A	-$287.86M	-$3.15	N/A
Grifols	$8.51B	0.65	$454.82M	$0.19	43.11

Compass Pathways currently has a consensus target price of $20.58, indicating a potential upside of 89.36%. Grifols has a consensus target price of $10.00, indicating a potential upside of 22.10%. Given Compass Pathways' stronger consensus rating and higher possible upside, equities research analysts clearly believe Compass Pathways is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Pathways	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.92
Grifols	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

Compass Pathways has a beta of 2.39, indicating that its share price is 139% more volatile than the broader market. Comparatively, Grifols has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market.

Summary

Compass Pathways beats Grifols on 9 of the 16 factors compared between the two stocks.

Get Compass Pathways News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CMPS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CMPS vs. The Competition

Export

Metric	Compass Pathways	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.36B	$8.16B	$6.30B	$12.12B
Dividend Yield	N/A	3.19%	2.80%	5.36%
P/E Ratio	-3.45	21.35	21.04	25.21
Price / Sales	N/A	16.42	530.38	73.06
Price / Cash	N/A	80.63	43.18	55.00
Price / Book	4.49	5.70	9.91	6.94
Net Income	-$287.86M	$180.93M	$3.55B	$335.25M
7 Day Performance	-0.82%	2.05%	-0.30%	-0.70%
1 Month Performance	14.90%	-1.79%	-2.34%	-0.90%
1 Year Performance	135.28%	0.85%	30.89%	29.67%

Compass Pathways Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CMPS Compass Pathways	3.7928 of 5 stars	$10.87 +7.9%	$20.58 +89.4%	+131.5%	$1.36B	N/A	N/A	120	Trending News Earnings Report Options Volume Analyst Revision
IMVT Immunovant	1.0291 of 5 stars	$26.53 -3.5%	$32.44 +22.3%	+78.8%	$5.60B	N/A	N/A	120	Trending News Earnings Report Insider Trade Gap Up
COGT Cogent Biosciences	2.2402 of 5 stars	$31.36 -4.0%	$43.73 +39.4%	+527.5%	$5.58B	N/A	N/A	80
XENE Xenon Pharmaceuticals	3.603 of 5 stars	$53.71 -1.3%	$77.07 +43.5%	+74.6%	$5.26B	$7.50M	N/A	210
APLS Apellis Pharmaceuticals	1.5109 of 5 stars	$41.03 flat	$35.72 -12.9%	+132.2%	$5.25B	$1.11B	40.23	770	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CMPS) was last updated on 5/20/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compass Pathways (CMPS) Competitors

CMPS vs. IMVT, COGT, XENE, APLS, and GRFS

How does Compass Pathways compare to Immunovant?

Summary

How does Compass Pathways compare to Cogent Biosciences?

Summary

How does Compass Pathways compare to Xenon Pharmaceuticals?

Summary

How does Compass Pathways compare to Apellis Pharmaceuticals?

Summary

How does Compass Pathways compare to Grifols?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPS vs. The Competition

Compass Pathways Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compass Pathways (CMPS) Competitors

CMPS vs. IMVT, COGT, XENE, APLS, and GRFS

How does Compass Pathways compare to Immunovant?

Which has more risk & volatility, CMPS or IMVT?

Do analysts rate CMPS or IMVT?

Which has higher earnings & valuation, CMPS or IMVT?

Does the media prefer CMPS or IMVT?

Do insiders & institutionals believe in CMPS or IMVT?

Is CMPS or IMVT more profitable?

Summary

How does Compass Pathways compare to Cogent Biosciences?

Which has more risk & volatility, COGT or CMPS?

Do institutionals & insiders hold more shares of COGT or CMPS?

Is COGT or CMPS more profitable?

Which has stronger valuation & earnings, COGT or CMPS?

Do analysts rate COGT or CMPS?

Does the media refer more to COGT or CMPS?

Summary

How does Compass Pathways compare to Xenon Pharmaceuticals?

Is CMPS or XENE more profitable?

Do insiders and institutionals hold more shares of CMPS or XENE?

Do analysts prefer CMPS or XENE?

Does the media refer more to CMPS or XENE?

Which has more volatility and risk, CMPS or XENE?

Which has preferable valuation and earnings, CMPS or XENE?

Summary

How does Compass Pathways compare to Apellis Pharmaceuticals?

Is APLS or CMPS more profitable?

Does the media favor APLS or CMPS?

Which has preferable earnings and valuation, APLS or CMPS?

Do analysts rate APLS or CMPS?

Which has more risk and volatility, APLS or CMPS?

Do insiders & institutionals believe in APLS or CMPS?

Summary

How does Compass Pathways compare to Grifols?

Do institutionals and insiders believe in CMPS or GRFS?

Is CMPS or GRFS more profitable?

Does the media favor CMPS or GRFS?

Which has higher valuation and earnings, CMPS or GRFS?

Do analysts prefer CMPS or GRFS?

Which has more risk & volatility, CMPS or GRFS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPS vs. The Competition

Compass Pathways Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools